Oculis Holding AG OCS
Updated: 18 Jun 2026
No signal published yet
We already track Oculis Holding AG and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Oculis Holding AG? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Oculis Holding AG free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On May 29, 2026, Oculis announced that its Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema failed to meet primary endpoints, resulting in the cancellation of its planned FDA filing. In June 2026, the company shifted focus to its remaining pipeline, randomizing the first patient in the PREDICT-1 trial for dry eye disease. Several law firms have since launched investigations into the company regarding potential securities law violations following the trial failure.
What Firelda Watch includes for Oculis Holding AG
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Oculis Holding AG? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Oculis Holding AG free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more